Tag: SAFE

GAITHERSBURG, Md., July 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016^® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration for Strategic Preparedness and Response (ASPR), part of the U. S. Department of Health and Human Services (HHS), for smallpox preparedness. ASPR exercised an option from its existing 10-year contract (75A50119C00037) for additional doses of VIGIV, a treatment for complications due to smallpox vaccination.

In this 2025 release, Ageless Shoulders expands its digital shoulder mobility system using traditional Indian club exercises to support joint flexibility, address frozen shoulder limitations, and meet rising search demand for non-surgical, at-home movement programs.

New 2025 Blueprint Reveals How Households Are Preparing for Water Disruptions With Smart, Off-Grid Technology

Rising search trends for “fireproof document safe,” “estate planning organizer,” and “emergency binder kit” spotlight ICE Box System as a non-digital solution for families protecting vital records and valuables at home.

DRML Miner introduces automated XRP rewards with AI-optimized contract options

Clinicians’ Choice Fat Burner for Women, PhenQ: Clinically Endorsed by 800 Healthcare Professionals Launched Over the Counter in the USA and Worldwide.

SANTA BARBARA, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- Public safety advocacy group The Dawn Project has called on legislators to take action to ban Tesla’s Full Self-Driving software from public roads over the litany of critical safety defects uncovered by the group’s safety tests of the software.

WESTON, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, today announced its entry into a warrant inducement agreement with a single institutional investor of the Company. Terms of the warrant inducement agreement include the immediate exercise of Series A-2 Warrants to purchase up to 957,200 shares of common stock (the “Series A-2 Warrants”) and Series A-3 Warrants to purchase up to 2,105,265 shares of common stock (the “Series A-3 Warrants,” and together with the Series A-2 Warrants, the “Existing Warrants”) at a reduced exercise price of $0.67. Gross cash proceeds were approximately $2.0 million before deducting financial advisor fees and other transaction expenses. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.